Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cancer Med. 2023 Jun;12(11):12495-12503. doi: 10.1002/cam4.5961. Epub 2023 Apr 16.
Patients with brain oligometastases have better prognosis than those with synchronous extracranial metastases in non-small cell lung cancer (NSCLC). However, studies focusing on intracranial-only recurrence after curative surgery remained scarce. This study aimed to explore distinct features of patients with exclusive brain relapse after resection of lung adenocarcinoma.
Records were retrospectively reviewed of 2809 patients who had complete resection and pathologically confirmed stage IB-IIIA NSCLC in our hospital from October 2012 to September 2019. Patients were enrolled if they were adenocarcinoma and developed intracranial recurrence thereafter. They were divided into two groups depending on whether they had synchronous extracranial metastases. Clinical and pathological features of patients enrolled were collected and compared between groups.
Ninety-seven lung adenocarcinoma patients with intracranial recurrences were enrolled. The median follow-up time was 40 months. Fifty patients (51.5%) had brain oligometastases and 47 patients had synchronous extracranial metastases (ECM). Multivariate logistic regression suggested EGFR-sensitive mutation and male sex were positively correlated to brain-only recurrence (OR = 2.59, 95%CI 1.04-6.84 and OR = 2.58, 95% CI 1.05-6.75), while higher clinical stage was associated with synchronous ECM (stage II (OR = 0.33, 95%CI 0.09-1.14) or stage IIIA (OR = 0.54, 95%CI 0.20-1.38) versus stage I). No other pathological feature (lymphovascular invasion, visceral pleural invasion, low tumor differentiation, etc.) or adjuvant chemotherapy was associated with intracranial-only relapse after complete resection of primary tumor.
Among patients with brain relapse after resection of lung adenocarcinoma, patients with EGFR mutations might have intracranial relapse only without synchronous extracranial metastases. Further prospective studies are warranted to verify this.
脑寡转移患者的预后优于非小细胞肺癌(NSCLC)中同时性颅外转移患者。然而,针对根治性手术后单纯颅内复发的研究仍然很少。本研究旨在探讨肺腺癌切除术后单纯脑复发患者的不同特征。
回顾性分析了 2012 年 10 月至 2019 年 9 月我院 2809 例完全切除并经病理证实为 IB-IIIA 期 NSCLC 的患者的记录。如果患者为腺癌,且此后发生颅内复发,则纳入研究。根据是否同时存在颅外转移,将患者分为两组。收集并比较两组患者的临床和病理特征。
共纳入 97 例肺腺癌颅内复发患者。中位随访时间为 40 个月。50 例(51.5%)患者存在脑寡转移,47 例患者存在同时性颅外转移(ECM)。多因素 logistic 回归表明,EGFR 敏感突变和男性与单纯脑复发呈正相关(OR=2.59,95%CI 1.04-6.84 和 OR=2.58,95%CI 1.05-6.75),而较高的临床分期与同时性 ECM 相关(II 期(OR=0.33,95%CI 0.09-1.14)或 IIIA 期(OR=0.54,95%CI 0.20-1.38)与 I 期相比)。其他病理特征(脉管侵犯、内脏胸膜侵犯、低肿瘤分化等)或辅助化疗与原发性肿瘤完全切除后单纯颅内复发无关。
在肺腺癌切除术后发生脑复发的患者中,EGFR 突变患者可能仅有颅内复发而无同时性颅外转移。需要进一步的前瞻性研究来验证这一点。